xav-19
Animal productexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2020 (NCT04453384)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Spike glycoproteinImmunity, passive
Spike glycoprotein immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04928430 | Phase 2/Phase 3 (Phase 3) | Apr 28, 2021 | Xenothera SAS |
| NCT04453384 | Phase 2 | Sep 1, 2020 | BPIfrance, University of Nantes, Xenothera SAS |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xenothera SAS | For profit | 2 | 1 | 2 | 2020 |
| BPIfrance | For profit | 1 | 0 | 1 | 2020 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1